


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 14, 2003

Signature:   
(Thomas J. Wrona, Ph.D.)

# 11/B 5/20

Docket No.: 30566/30029  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Rosanne M. Crooke, *et al.*

Application No.: 09/920,033

Group Art Unit: 1635

Filed: August 1, 2001

Examiner: J. Epps

For: ANTISENSE MODULATION OF  
APOLIPOPROTEIN B EXPRESSION

RECEIVED  
MAY 19 2003  
TECH CENTER 1600/2900

**I. AMENDMENT AND II. RESPONSE TO THE OFFICE ACTION  
OF JANUARY 14, 2003**


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**I. AMENDMENT**

Please amend the above-identified U.S. patent application as follows:

**In the Claims**

- 
1. (Twice Amended) A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B [(SEQ ID NO: 3)], wherein said compound specifically hybridizes with nucleotides 1-128 or nucleotides 149-14121 as set forth in SEQ ID NO: 3 and inhibits the expression of a nucleic acid molecule encoding apolipoprotein B.
  2. (Original) The compound of claim 1 which is an antisense oligonucleotides.
  3. (Canceled)
  4. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.